Cellth Systems recently reached a licensing deal with UM Ventures to expand development of its medical device that can help provide insight into how to treat cancer as it spreads.
In Baltimore, the technology was developed in the lab of University of Maryland School of Medicine Professor Stuart Martin. Research conducted at the University of Maryland-College Park also contributed to its development.
Cellth Systems focuses in on Circulating Tumor Cells. They serve as early indicators that cancer is spreading, but often require different medication to treat than initial cancer cells, said Cellth CEO Richard Hughen. He calls them “sinister agents in cancer.”
READ FULL ARTICLE HERE
